# NCT04468061 (NCT04468061)

> Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04468061
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer; Triple Negative Breast Cancer; PD-L1 Negative
- Interventions: Sacituzumab Govitecan; Pembrolizumab
- Enrollment: 110
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 4
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04468061